Table 2 Levels of access to commonly used second-line antiretroviral drugs in TREAT Asia and IeDEA Southern Africa
| Â | Categories of drug access | |||||||
|---|---|---|---|---|---|---|---|---|
Antiretroviral* | Easy to access | Somewhat difficult to access | Difficult to access | Cannot or do not access | ||||
| Â | TA | SA | TA | SA | TA | SA | TA | SA |
ABC | 38% | 60% | 6% | 0 | 19% | 30% | 38% | 10% |
ddI | 100% | 90% | 0 | 0 | 0 | 0 | 0 | 10% |
TDF | 50% | 10% | 38% | 30% | 0 | 10% | 13% | 50% |
ATV | 19% | 10% | 13% | 0 | 6% | 0 | 63% | 90% |
IDV | 56% | 10% | 6% | 10% | 6% | 20% | 31% | 60% |
LPV/r, liquid | 69% | 80% | 13% | 20% | 0 | 0 | 19% | 0 |
LPV/r, paediatric tablet | 50% | 10% | 0 | 10% | 19% | 10% | 31% | 70% |
LPV/r, adult tablet | 81% | 100% | 0 | 0 | 13% | 0 | 6% | 0 |
LPV/r, adult capsule | 31% | 60% | 19% | 20% | 6% | 0 | 44% | 20% |
NFV | 6% | 20% | 13% | 0 | 0 | 20% | 81% | 60% |
RTV, liquid | 13% | 50% | 19% | 20% | 19% | 0 | 50% | 30% |
RTV, capsule | 38% | 50% | 13% | 30% | 0 | 0 | 50% | 20% |
SQV | 13% | 10% | 13% | 10% | 25% | 30% | 50% | 50% |